Workflow
COSCIENS Biopharma Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate Update
CSCICosciens Biopharma Inc(CSCI) GlobeNewswire· Globenewswire·2025-05-13 21:05

Core Viewpoint - COSCIENS Biopharma Inc. has repositioned itself as a pure-play natural-based product company following a strategic review and pipeline prioritization, while continuing efforts to streamline operations and cut costs [1] Financial Overview - The company reported a consolidated net loss of 3.7million,or3.7 million, or 1.16 loss per common share, for the first quarter of 2025, compared to a net loss of 1.4million,or1.4 million, or 0.76 loss per common share, for the same period in 2024 [6] - Total revenue for the first quarter of 2025 was 1.5million,downfrom1.5 million, down from 2.1 million in the same period in 2024, primarily due to a 0.7milliondecreaseinsalesofAvenanthramides,BetaGlucan,andOatOil[7]Operatingexpensesincreasedto0.7 million decrease in sales of Avenanthramides, Beta Glucan, and Oat Oil [7] - Operating expenses increased to 4.0 million from 2.7millioninthesameperiodin2024,mainlyduetohigherselling,general,andadministrativecostsfollowingamerger[13]CashPositionAsofMarch31,2025,thecompanyhad2.7 million in the same period in 2024, mainly due to higher selling, general, and administrative costs following a merger [13] Cash Position - As of March 31, 2025, the company had 13.8 million in cash and cash equivalents [5] Clinical Development - The company is advancing its Phase 2 clinical trial for Avenanthramide tablets, having successfully completed Phase 1 with no significant adverse events observed [4] - The Phase 2a clinical efficacy study commenced on March 15, 2025, with the first cohort of 10 patients completing their treatment, and the Data and Safety Monitoring Board recommended continuation with a second cohort [4] Product Development - COSCIENS is working on a new portfolio of nutraceuticals, including an Oat Beta Glucan Chewable Bar for cholesterol reduction and a Yeast Beta Glucan Powder as an immune booster [4] - The company has completed the scale-up project for Pressurized Gas eXpanded Technology (PGX) at its Edmonton facility, ready to produce Yeast Beta Glucan at a small-scale commercial level [4]